- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.03. | Acadia drug fails schizophrenia trial, setting back company's expansion plans | ||
| 11.03. | Roche, following setbacks, turns to its next Alzheimer's drug | ||
| 11.03. | Boehringer, Sosei Heptares team up in schizophrenia drug deal | ||
| 11.03. | Amylyx CEOs look for a path forward following major setback | ||
| 11.03. | J&J's growing rare disease focus brings a potential multi-use treatment to the table | ||
| 11.03. | Biotech stock fundings headed for best quarter in 3 years, Jefferies says | ||
| 11.03. | Advanced technologies in unlocking the future of drug manufacturing | ||
| 11.03. | Can using SDoH data help identify patient populations who could benefit from weight loss drugs? | ||
| 08.03. | FDA clears use of Novo's obesity drug to protect heart health | ||
| 08.03. | FDA delays decision on Lilly's closely watched Alzheimer's drug | ||
| 08.03. | Why Cigna is capping cost increases for pricey obesity drugs | ||
| 08.03. | Amylyx ALS drug fails crucial study, putting company's future in doubt | ||
| 07.03. | NodThera says inflammation drug has positive effect in Parkinson's | ||
| 07.03. | Novo's latest obesity pill spurs major weight loss in small trial | ||
| 07.03. | Biden proposes strengthening Medicare's drug pricing power | ||
| 07.03. | Boundless Bio, a Bayer-backed cancer biotech, seeks an IPO | ||
| 06.03. | European VC Invivo readies its latest fund to back new biotechs | ||
| 06.03. | Alumis, taking aim at Bristol Myers, pulls in $259M for TYK2 drug work | ||
| 06.03. | Gilead bets on 'trispecifics' in latest cancer drug deal | ||
| 06.03. | Regenxbio data suggest 'niche' in Duchenne gene therapy | ||
| 06.03. | Sionna raises another $182M to challenge Vertex in cystic fibrosis | ||
| 05.03. | Alnylam, Roche blood pressure drug scores in second mid-stage trial | ||
| 05.03. | Bayer isn't splitting up, for now | ||
| 05.03. | Apogee data hint at potential for long-lasting eczema drug | ||
| 05.03. | Biotech IPOs heated up to start 2024. Will the surge last? |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
